Drozitumab

Drug Profile

Drozitumab

Alternative Names: Anti-Death Receptor 5 monoclonal antibody - Genentech; Anti-DR5 mAb - Genentech; Anti-TRAIL Receptor-2 monoclonal antibody - Genentech; Apomab; PRO-95780; RG7425

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; TRAIL receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Chondrosarcoma; Colorectal cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 05 Jun 2007 Data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2007) added to the adverse events, pharmacokinetics, and Cancer therapeutic trials sections
  • 03 Jun 2007 Phase-II clinical trials in Non-Hodgkin's lymphoma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top